TYRA vs. INVA, VRNA, LQDA, OCUL, BCYC, OPK, IRWD, ABVX, SAVA, and ELVN
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Innoviva (INVA), Verona Pharma (VRNA), Liquidia (LQDA), Ocular Therapeutix (OCUL), Bicycle Therapeutics (BCYC), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), ABIVAX Société Anonyme (ABVX), Cassava Sciences (SAVA), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of 0.00%. Tyra Biosciences' return on equity of 28.94% beat Innoviva's return on equity.
In the previous week, Tyra Biosciences had 1 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Tyra Biosciences and 2 mentions for Innoviva. Tyra Biosciences' average media sentiment score of 1.56 beat Innoviva's score of 0.64 indicating that Innoviva is being referred to more favorably in the media.
Innoviva has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences has a consensus target price of $23.50, suggesting a potential upside of 32.84%. Given Innoviva's higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Innoviva.
99.1% of Innoviva shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 1.4% of Innoviva shares are held by insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Innoviva received 277 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 62.07% of users gave Tyra Biosciences an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Summary
Innoviva beats Tyra Biosciences on 10 of the 16 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
